NASDAQ:GRFSGRIFOLS S A/S Stock Price, Forecast & News

GRIFOLS S A/S's stock was trading at $20.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GRFS stock has decreased by 8.2% and is now trading at $18.70. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GRIFOLS S A/S.

GRIFOLS S A/S is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for GRIFOLS S A/S.

GRIFOLS S A/S (NASDAQ:GRFS) posted its quarterly earnings data on Tuesday, April, 21st. The biotechnology company reported $0.25 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.24 by $0.01. The biotechnology company had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $1.40 billion. GRIFOLS S A/S had a return on equity of 11.92% and a net margin of 13.31%. View GRIFOLS S A/S's earnings history.

GRIFOLS S A/S announced a semi-annual dividend on Thursday, October 31st. Stockholders of record on Tuesday, December 3rd will be paid a dividend of $0.169 per share on Wednesday, December 11th. This represents a yield of 1.3%. The ex-dividend date of this dividend is Monday, December 2nd. This is a positive change from GRIFOLS S A/S's previous semi-annual dividend of $0.15. View GRIFOLS S A/S's dividend history.

Shares of GRIFOLS S A/S split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were payable to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

Media coverage about GRFS stock has been trending somewhat positive on Saturday, InfoTrie reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. GRIFOLS S A/S earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news about GRIFOLS S A/S.

GRIFOLS S A/S saw a increase in short interest in June. As of June 15th, there was short interest totaling 2,500,000 shares, an increase of 13.6% from the May 31st total of 2,200,000 shares. Based on an average daily trading volume, of 985,300 shares, the short-interest ratio is currently 2.5 days. Approximately 1.0% of the shares of the company are sold short. View GRIFOLS S A/S's Current Options Chain.

Some companies that are related to GRIFOLS S A/S include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Beigene (BGNE), GALAPAGOS NV/S (GLPG), Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA) and Catalent (CTLT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Allergan (AGN), Nektar Therapeutics (NKTR) and Johnson & Johnson (JNJ).

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GRFS stock can currently be purchased for approximately $18.70.

GRIFOLS S A/S has a market capitalization of $12.86 billion and generates $5.71 billion in revenue each year. The biotechnology company earns $700.16 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 22,244 workers across the globe.

The official website for GRIFOLS S A/S is www.grifols.com.

GRIFOLS S A/S's mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-0000 or via email at [email protected]